Suehiro M, Scheffel U, Ravert H T, Dannals R F, Wagner H N
Division of Nuclear Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2179.
Life Sci. 1993;53(11):883-92. doi: 10.1016/0024-3205(93)90440-e.
The in vivo behavior of the stereoisomers of [11C]McN5652, a highly potent serotonin (5-HT) uptake blocker, was determined to evaluate their utility as radiotracers for imaging 5-HT uptake sites by positron emission tomography (PET). After intravenous injection into mice, 11CMcN5652 showed markedly higher uptake and longer retention in regions with high density of 5-HT uptake sites than the [11C]-labeled racemic mixture, while 11CMcN5652 washed out rapidly. With the 11C-enantiomer, the ratio between hypothalamus and cerebellum reached 6 at 90 minutes. The binding of 11CMcN5652 was inhibited by 45-73% by pre-injection of 5 mg/kg of paroxetine, a selective 5-HT uptake blocker, in all regions examined except cerebellum where no significant effect of the drug was observed. 11CMcN5652 showed no specific binding in any of the regions. The [11C]-labeled cis isomer, [11C]McN5655, revealed surprisingly low brain penetration and showed no significantly higher uptake in regions of interest than cerebellum. These results suggest that 11CMcN5652 is a promising candidate as a PET radiotracer for studying 5-HT uptake sites in vivo.